EcoDrugPlus

Solute Carrier Family 6 Member 2

Ensembl ID : ENSUPAG00010014487
Gene Symbol: SLC6A2
3 Cross references
202 Possible Orthologues:

Solute Carrier Family 6 Member 3

Ensembl ID : ENSUPAG00010011424
Gene Symbol: SLC6A3
3 Cross references
166 Possible Orthologues:

Solute Carrier Family 6 Member 4

Ensembl ID : ENSUPAG00010018800
Gene Symbol: SLC6A4
1 Cross references
203 Possible Orthologues:

Solute Carrier Family 6 Member 9

Ensembl ID : ENSUPAG00010021142
Gene Symbol: SLC6A9
1 Cross references
207 Possible Orthologues:

Solute Carrier Family 9 Member A3

Ensembl ID : ENSUPAG00010019381
Gene Symbol: SLC9A3
3 Cross references
234 Possible Orthologues:

Somatostatin Receptor 1

Ensembl ID : ENSUPAG00010021508
Gene Symbol: SSTR1
3 Cross references
158 Possible Orthologues:

Somatostatin Receptor 2

Ensembl ID : ENSUPAG00010002676
Gene Symbol: SSTR2
3 Cross references
263 Possible Orthologues:

Somatostatin Receptor 3

Ensembl ID : ENSUPAG00010004643
Gene Symbol: SSTR3
3 Cross references
249 Possible Orthologues:

Somatostatin Receptor 4

Ensembl ID : ENSUPAG00010009751
Gene Symbol: SSTR4
1 Cross references
100 Possible Orthologues:

Somatostatin Receptor 5

Ensembl ID : ENSUPAG00010014041
Gene Symbol: SSTR5
3 Cross references
256 Possible Orthologues:

Sphingosine Kinase 2

Ensembl ID : ENSUPAG00010012702
Gene Symbol: SPHK2
1 Cross references
209 Possible Orthologues:

Sphingosine-1-Phosphate Receptor 1

Ensembl ID : ENSUPAG00010005626
Gene Symbol: S1PR1
1 Cross references
200 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).